According to analysts Opko Health Inc (NASDAQ:OPK)'s minimum EPS for the current quarter is at $-0.07 and can go high up to $-0.03. The institutional investor purchased 120,325 shares of the biotechnology company's stock, valued at approximately $963,000. Oracle Investment Management Inc.'s holdings in Opko Health were worth $28,264,000 as of its most recent filing with the SEC. (NASDAQ:OPK) shares with value of $63,135 were bought by LERNER RICHARD A. Logal Adam also sold $911,674 worth of Opko Health Inc. 115 funds opened positions while 706 raised stakes. BlackRock Inc. now owns 22,645,285 shares of the biotechnology company's stock worth $181,163,000 after buying an additional 22,449,752 shares during the period.
Bank Hapoalim BM purchased a new stake in Opko Health, Inc. Private Advisor Group LLC now owns 49,521 shares of the biotechnology company's stock valued at $377,000 after buying an additional 10,670 shares during the last quarter. AQR Capital Management LLC acquired a new position in Opko Health during the fourth quarter valued at $105,000. State Street Corp now owns 7,787,875 shares of the biotechnology company's stock worth $72,427,000 after buying an additional 226,132 shares in the last quarter. Finally, RK Asset Management LLC raised its position in Opko Health by 0.4% in the first quarter. Capstone Asset Management Co. now owns 17,646 shares of the biotechnology company's stock valued at $141,000 after buying an additional 1,400 shares during the period. On average, equities analysts predict that Opko Health will post ($0.20) earnings per share for the current year. The Beta for the stock stands at 1.86.
If we look at stock performance in last active day trading, we see that stock has moved remains unchanged to end the day at $5.24.
The stock Hit its 1-year high of $12.15 on 12/15/16 and its 1-year low price of $5.99 on 06/01/17.
In the market the company is trading unchanged from yesterday's close of $6.69.
According to the analysts, Opko Health Inc (NASDAQ:OPK) is expected to announce $-0.05/share EPS for the current quarter. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.04) by $0.02. The company had revenue of $296.10 million for the quarter, compared to the consensus estimate of $313.36 million. The net profit margin for the company is reported at 1.60% while the weekly performance for the same has been recorded at -3.40%. Opko Health Inc. (NYSE:OPK) has declined 32.62% since June 23, 2016 and is downtrending. They expect $0.74 earnings per share, up 2.78% or $0.02 from last year's $0.72 per share.
ILLEGAL ACTIVITY NOTICE: This piece was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and worldwide copyright legislation. The legal version of this report can be accessed at https://transcriptdaily.com/2017/06/23/financial-counselors-inc-has-125000-position-in-opko-health-inc-opk-updated-updated.html.
A number of research firms have recently issued reports on OPK. Guggenheim began coverage on shares of Opko Health in a research note on Tuesday, March 14th. Jefferies Group LLC reaffirmed a "hold" rating and set a $8.00 price objective on shares of Opko Health in a report on Monday, June 12th. A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range. The company presently has a consensus rating of "Hold" and an average target price of $16.58. HSIAO JANE PH D had bought 40,000 shares worth $278,705 on Wednesday, May 10. After a recent check, Mobileye NV (NYSE:MBLY) shares price moved up from its 50 days moving average with 1.32% and remote positively from 200 days moving average with 30.02%. Following the purchase, the director now directly owns 350,340 shares in the company, valued at $2,161,597.80. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. The stock was purchased at an average cost of $8.14 per share, for a total transaction of $74,888.00. The disclosure for this purchase can be found here. Insiders bought 2,796,400 shares of company stock valued at $19,089,481 in the last quarter. Globenewswire.com's article titled: "OPKO Health Provides Commercial Update for RAYALDEE" and published on June 05, 2017 is yet another important article. It operates through Diagnostics, and Pharmaceutical segments. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations.